Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Accounts Payables (2016 - 2025)

Sanofi (SNY) has disclosed Accounts Payables for 10 consecutive years, with $8.6 billion as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 6.19% to $8.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 billion through Dec 2025, up 6.19% year-over-year, with the annual reading at $8.3 billion for FY2025, 1.76% up from the prior year.
  • Accounts Payables hit $8.6 billion in Q4 2025 for Sanofi, up from $8.1 billion in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $8.6 billion in Q4 2025 to a low of $7.0 billion in Q4 2022.
  • Historically, Accounts Payables has averaged $7.7 billion across 5 years, with a median of $7.9 billion in 2023.
  • Biggest five-year swings in Accounts Payables: decreased 1.68% in 2022 and later increased 13.43% in 2023.
  • Year by year, Accounts Payables stood at $7.1 billion in 2021, then fell by 1.68% to $7.0 billion in 2022, then increased by 13.43% to $7.9 billion in 2023, then rose by 2.34% to $8.1 billion in 2024, then rose by 6.19% to $8.6 billion in 2025.
  • Business Quant data shows Accounts Payables for SNY at $8.6 billion in Q4 2025, $8.1 billion in Q4 2024, and $7.9 billion in Q4 2023.